✦ LIBER ✦

Clinical characteristics and outcome of patients with cirrhosis and refractory ascites

✍ Scribed by Richard Moreau; Paul Delègue; Fabienne Pessione; Sophie Hillaire; François Durand; Didier Lebrec; Dominique-Charles Valla

Book ID: 111237300
Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 129 KB
Volume: 24
Category: Article
ISSN: 0106-9543
DOI: 10.1111/j.1478-3231.2004.0991.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical Presentation and Outcomes of Pa

Clinical Presentation and Outcomes of Patients With Cirrhosis and Hemorrhagic Ascites

✍ Urrunaga, Nathalie H. ;Singal, Amit G. ;Cuthbert, Jennifer A. ;Rockey, Don C. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Complicated hernia presentation in patie

Complicated hernia presentation in patients with advanced cirrhosis and refractory ascites: Management and outcome

✍ Dana A. Telem; Thomas Schiano; Celia M. Divino 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 98 KB

Beta-blockers in patients with cirrhosis

Beta-blockers in patients with cirrhosis and refractory ascites

✍ Albillos Agustín; Zamora Javier 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 296 KB 👁 2 views

We read with interest the reviews by Ghouri et al. 1 and Martinez et al. 2 Ghouri et al. analyzed the association of nonalcoholic fatty liver disease (NAFLD) with cardiovascular disease (CVD) and concluded that although a diagnosis of NAFLD should prompt diabetes screening, it is insufficient for co

Beta-blockers in cirrhosis patients with

Beta-blockers in cirrhosis patients with refractory ascites

✍ Robins, Anne; Bowden, Anne; Watson, William; Smith, Fiona; Gelson, William; Grif 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 478 KB

Outcome after transjugular intrahepatic

Outcome after transjugular intrahepatic portal-systemic shunt for refractory ascites in patients with advanced cirrhosis

✍ SHRESTHA, R 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB

Effects of beta-blockers on survival for

Effects of beta-blockers on survival for patients with cirrhosis and refractory ascites

✍ Gin-Ho Lo 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 632 KB

Shorter duration and lower dose of peginterferon alfa-2a therapy results in inferior HBeAg seroconversion rates compared with the duration and dose of 48 weeks and 180 lg: NEPTUNE study.